Evidence map›Paper›PMID 29409459›Full record

ArticleBMC cancer2018

A three-lncRNA signature predicts overall survival and disease-free survival in patients with esophageal squamous cell carcinoma.

Guo-Wei Huang, Yu-Jie Xue, Zhi-Yong Wu, Xiu-E Xu, Jian-Yi Wu, Hui-Hui Cao, Ying Zhu, Jian-Zhong He, Chun-Quan Li, En-Min Li and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. A nomogram based on 4-lncRNAs signature for improving prognostic prediction of hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Multifaceted Roles of Long Non-coding RNAs in Head and Neck Cancer.Advances in experimental medicine and biology · 2021
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guo-Wei HuangInstitute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong, 515041, China.
Yu-Jie XueInstitute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong, 515041, China.
Zhi-Yong WuInstitute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong, 515041, China.
Xiu-E XuInstitute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong, 515041, China.
Jian-Yi WuThe Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, Guangdong, People's Republic of China.
Hui-Hui CaoInstitute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong, 515041, China.
Ying ZhuInstitute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong, 515041, China.
Jian-Zhong HeInstitute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong, 515041, China.
Chun-Quan LiInstitute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong, 515041, China.
En-Min LiThe Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041, Guangdong, People's Republic of China. nmli@stu.edu.cn.
Li-Yan XuInstitute of Oncologic Pathology, Shantou University Medical College, No. 22, Xinling Road, Shantou, Guangdong, 515041, China. lyxu@stu.edu.cn.

Funding

the National Science Foundation of China 61602292the National Science Foundation of China 81472613the National Science Foundation of China 81572341the Natural Science Foundation of China-GuangDong Joint Fund U1301227
6 · The paper itself

Abstract

backgroundIncreasing evidence shows that dysregulated long non-coding RNAs (lncRNAs) can serve as potential biomarkers for cancer prognosis. However, lncRNA signatures, as potential prognostic biomarkers for esophageal squamous cell carcinoma (ESCC), have been seldom reported.

methodsBased on our previous transcriptome RNA sequencing analysis from 15 paired ESCC tissues and adjacent normal tissues, we selected 10 lncRNAs with high score rank and characterized the expression of those lncRNAs, by qRT-PCR, in 138 ESCC and paired adjacent normal samples. These 138 patients were divided randomly into training (n = 77) and test (n = 59) groups. A prognostic signature of lncRNAs was identified in the training group and validated in the test group and in an independent cohort (n = 119). Multivariable Cox regression analysis evaluated the independence of the signature in overall survival (OS) and disease-free survival (DFS) prediction. GO and KEGG pathway analysis, combined with cell transwell and proliferation assays, are applied to explore the function of the three lncRNAs.

resultsA novel three-lncRNA signature, comprised of RP11-366H4.1.1 (ENSG00000248370), LINC00460 (ENSG00000233532) and AC093850.2 (ENSG00000230838), was identified. The signature classified patients into high-risk and low-risk groups with different overall survival (OS) and disease-free survival (DFS). For the training group, median OS: 23.1 months vs. 39.1 months, P < 0.001; median DFS: 15.2 months vs. 33.3 months, P < 0.001. For the test group, median OS: 23 months vs. 59 months, P < 0.001; median DFS: 16.4 months vs. 50.8 months, P < 0.001. For the independent cohort, median OS: 22.4 months vs. 60.4 months, P < 0.001). The signature indicates that patients in the high-risk group show poor OS and DFS, whereas patients with a low-risk group show significantly better outcome. The independence of the signature was validated by multivariable Cox regression analysis. GO and KEGG pathway analysis for 588 protein-coding genes-associated with the three lncRNAs indicated that the three lncRNAs were involved in tumorigenesis. In vitro assays further demonstrated that the three lncRNAs promoted the migration and proliferation of ESCC cells.

conclusionsThe three-lncRNA signature is a novel and potential predictor of OS and DFS for patients with ESCC.

Indexed as

Gene Expression Regulation, NeoplasticBiomarkers, TumorCarcinoma, Squamous CellCell Line, TumorDisease-Free SurvivalEsophageal NeoplasmsFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisProportional Hazards ModelsRNA, Long NoncodingBiomarkers, TumorRNA, Long NoncodingAC093850.2Disease-free survivalEsophageal squamous cell carcinomaLINC00460LncRNAsOverall survivalRP11-366H4.1.1Signature

Identifiers

PMID29409459
PMCPMC5801805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.